Pronouns: he, him, his
Kabir Cooppan-Boyd
His Role
As Program Manager and a founding team member at Beckley Academy, Kabir oversees the development, implementation, and evaluation of educational programs and collaborative projects. He works closely with subject matter experts to create evidence-based curricula aligned with both the latest research as well as historic wisdom traditions. Kabir also builds relationships with key stakeholders, including healthcare professionals, academic institutions, and industry partners, while facilitating seminars for professionals in the field. In his role, Kabir is dedicated to ensuring the highest standards of quality and accessibility in Beckley’s offerings, fostering a meaningful impact in the field of psychedelic education and therapy.
His Story
Kabir’s interest in psychedelic medicine, particularly its therapeutic applications, began the summer after high school during an internship with MAPS in the Santa Cruz office. MAPS’ commitment to widespread integrated health and a strong workplace community nurtured his enduring desire to expand access to psychedelic medicines. He majored in psychology and wrote his senior thesis on psilocybin therapy as a treatment for existential distress.
After graduation, Kabir volunteered for the Measure 109 Psilocybin Therapy campaign in Oregon. The campaign’s fast-paced and inspirational environment further solidified his passion for making psychedelic therapy accessible. Following the campaign’s success, Kabir joined the Center for Consciousness Medicine (CCM), where he deepened his enthusiasm for academic research and equity-oriented approaches to psychedelic therapy.
His Why
A combination of transformative personal experiences and early exposure to groundbreaking clinical research inspired Kabir to pursue a career in psychedelic therapy. His work in Oregon on the Measure 109 campaign exposed him to thousands of individuals in desperate need of innovative treatment options. This experience instilled a lasting commitment to expanding the accessibility and equity of psychedelic therapy through education, training, and strategic collaboration.